Abstract: Poor prognosis and high mortality rates are frequently observed in patients with relapsed/refractory acute myeloid leukemia (R/R AML), making it a hard-to-cure disease. Venetoclax, a BCL-2 inhibitor, was approved for treating newly diagnosed AML in medically unfit adults and patients aged over 75 years. Recently, venetoclax combined with hypomethylating agents, chemotherapy, molecule inhibitors, and allogenic hematopoietic stem cell transplantation (allo-HSCT) has demonstrated promising prospects in treating R/R AML. Maintenance therapy with venetoclax after allo-HSCT was effective in preventing post-transplant relapse and increasing patients’ survival. Many clinical studies have also reported the safety of venetoclax because of its high tolerability and low incidence of associated adverse events. This review reports the latest clinical progress on venetoclax treatment for R/R AML and its associated adverse events .